Author

W. Nicholson Price II

  • FDA

    Praise for Price’s “Making Do in Making Drugs”

    Check out this nice write up of PFC Academic Fellow Nicholson Price‘s paper, Making Do in Making Drugs: Innovation Policy and Pharmaceutical Manufacturing, over at the Written Description IP blog.  Says blogger Camilla Alexandra Hrdy, “Price’s paper…

    Praise for Price’s “Making Do in Making Drugs”

  • Health Care Finance

    HBR/NEJM online forum on health care innovation

    By Nicholson Price For those of you who haven’t seen it yet, there’s a great ongoing online forum over at the joint Harvard Business Review and New England Journal of Medicine Insight Center on Leading…

    HBR/NEJM online forum on health care innovation

  • FDA

    Drug manufacturing’s innovation problem

    By Nicholson Price There’s a lot of talk and research about the drug industry, including its levels of innovation, its pricing patterns, transparency of clinical trials, industry changes over time, and how the industry is…

    Drug manufacturing’s innovation problem

  • Bioethics

    Experiment vs. innovative treatment in bacterial transplants

    By Nicholson Price There’s a fascinating and tragic story coming to its conclusion at UC Davis, which points at the fine line between clinical innovation and experimental treatment.  Two neurosurgeons just resigned, following the resignation…

    Experiment vs. innovative treatment in bacterial transplants

  • Bioethics

    Henrietta Lacks and the HeLa genome

    By Nicholson Price A few days ago, NIH announced an agreement with the family of Henrietta Lacks.  When she was being treated for an aggressive tumor, cells were taken without her consent or knowledge and used…

    Henrietta Lacks and the HeLa genome

  • Criminal Law

    Importing unapproved drugs: lethal injections and shortages

    By Nicholson Price In a unanimous opinion (pdf) in Cook v. FDA, the DC Circuit just held that FDA must prohibit the importation of misbranded or unapproved new drugs, including those made by unapproved manufacturers…

    Importing unapproved drugs: lethal injections and shortages

  • Health Care Reform

    Employer mandate delayed for a year.

    By Nicholson Price The employer mandate has been delayed for a year, until 2015.  Under this provision of the Affordable Care Act, all employers with more than 50 employees are obliged to provide health insurance…

    Employer mandate delayed for a year.

  • Biotechnology

    Reactions to Myriad, two weeks later

    By Nicholson Price Two weeks after the Supreme Court held isolated naturally occurring DNA unpatentable in Association for Molecular Pathology v. Myriad Genetics, Inc., there’s been quite a lot of commentary about the case’s implications…

    Reactions to Myriad, two weeks later

  • Antitrust

    Supreme Court deals a major blow to reverse-payment settlements.

    By Nicholson Price The Supreme Court keeps coming out with major opinions in the biotech/pharma area, with today seeing a major blow to reverse-payment settlements wherein brand-name pharma companies pay generic companies to delay their…

    Supreme Court deals a major blow to reverse-payment settlements.